Literature DB >> 249623

Comparative in vivo activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa.

M Kondo, K Tsuchiya.   

Abstract

The in vivo activities of cefsulodin, sulbenicillin, and gentamicin were compared in mice infected intraperitoneally with Pseudomonas aeruginosa. In mice infected with sulbenicillin- and gentamicin-susceptible strains, cefsulodin was about 12 to 60 times more active than sulbenicillin and had an activity similar to gentamicin. In mice, the activity of cefsulodin was independent whether the strains were resistant to gentamicin or not, but it was considerably affected by resistance of the strains to sulbenicillin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 249623      PMCID: PMC352419          DOI: 10.1128/AAC.14.1.151

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Laboratory studies with a new broad-spectrum penicillin, pirbenicillin.

Authors:  J A Retsema; A R English; J E Lynch
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  BB-K 8, a new semisynthetic aminoglycoside antibiotic.

Authors:  H Kawaguchi; T Naito; S Nakagawa; K I Fujisawa
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

3.  Mezlocillin: in vitro studies of a new broad-spectrum penicillin.

Authors:  G P Bodey; T Pan
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

4.  Cross-resistance of Pseudomonas to gentamicin and tobramycin.

Authors:  J L Brusch; M Barza; M G Bergeron; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-03       Impact factor: 5.191

5.  Antibiotic 6640. 3. Biological studies with antibiotic 6640, a new broad-spectrum aminoglycoside antibiotic.

Authors:  J A Waitz; E L Moss; E M Oden; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

6.  In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin.

Authors:  K Ueo; Y Fukuoka; T Hayashi; T Yasuda; H Taki; M Tai; Y Watanabe; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

7.  Comparative in vitro activities of SCE-129, sulbenicillin, gentamicin, and dibekacin against Pseudomonas.

Authors:  K Tsuchiya; M Kondo
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms.

Authors:  J J Rahal; M S Simberkoff; K Kagan; N H Moldover
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

9.  SCE-129, antipseudomonal cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; H Nagatomo
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

10.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

View more
  3 in total

Review 1.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

2.  Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; T S Yamashita; I Ackers; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

3.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.